NSAIDs have some mild GABA antagonistic properties and animal research indicate that some may even displace benzodiazepines from their binding site. However, NSAIDs taken in combination with fluoroquinolones cause a very significant increase in GABA antagonism, GABA toxicity, seizures, and other severe adverse effects. Imidazenil has received some research for management of benzodiazepine withdrawal, but is not currently used in withdrawal. Imipramine was found to statistically increase the discontinuation success rate. Melatonin augmentation was found to statistically increase the discontinuation success rate for people with insomnia. Phenobarbital, (a barbiturate), is used at "detox" or other inpatient facilities to prevent seizures during rapid withdrawal or cold turkey. The phenobarbital is followed by a one- to two-week taper, although a slow taper from phenobarbital is preferred. In a comparison study, a rapid taper using benzodiazepines was found to be superior to a phenobarbital rapid taper. Pregabalin may help reduce the severity of benzodiazepine withdrawal symptoms, and reduce the risk of relapse. Propranolol was not found to increase the discontinuation success rate. SSRI antidepressants have been found to have little value in the treatment of benzodiazepine withdrawal. Trazodone was not found to increase the discontinuation success rate. Inpatient treatment
Inpatient drug detox or rehabilitation facilities may be inappropriate for those who have become tolerant or dependent while taking the drug as prescribed, as opposed to recreational use. Such inpatient referrals may be traumatic for these individuals. Prognosis
A 2006 meta-analysis found evidence for the efficacy of stepped care: minimal intervention (e.g.
Another approach is the use of an autotransplant of a resected sigmoid colon using laparoscopic surgery; results are reported to be very good with the transplant becoming a functional vagina.Uterine transplantation has been performed in a number of people with MRKH, but the surgery is still in the experimental stage. Since ovaries are present, people with this condition can have genetic children through IVF with embryo transfer to a gestational carrier. Some also choose to adopt. In October 2014, it was reported that a month earlier a 36-year-old Swedish woman became the first woman with a transplanted uterus to give birth to a healthy baby. She was born without a uterus, but had functioning ovaries. She and the father went through IVF to produce 11 embryos, which were then frozen. Doctors at the University of Gothenburg then performed the uterus transplant, the donor being a 61-year-old family friend. One of the frozen embryos was implanted a year after the transplant, and the baby boy was born prematurely at 31 weeks after the mother developed pre-eclampsia.Promising research include the use of laboratory-grown structures, which are less subject to the complications of non-vaginal tissue, and may be grown using the womans own cells as a culture source. The recent development of engineered vaginas using the patients own cells has resulted in fully functioning vaginas capable of menstruation and orgasm in a number of patients showing promise of fully correcting this condition. Epidemiology
The prevalence remains sparsely investigated.